Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | GNG2 | P59768 | 2/20 | 0.57 |
| ▸ | GNB1 | P62873 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TERT | O14746 | 4/20 | 0.55 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235863 | 0.84 | NCF1 (0.63) | NCF1LMNAALDH1A1CASP1CASP7 | |
| SCHEMBL5456804 | 0.84 | BACE1 (0.55) | NCF1LMNAALDH1A1CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL30579056 | 0.82 | NCF1 (0.61) | NCF1LMNAALDH1A1CASP1CASP7 | |
| SCHEMBL6616973 | 0.81 | NCF1 (0.59) | NCF1ALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL437502 | 0.81 | NCF1 (0.59) | NCF1ALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL439684 | 0.81 | NCF1 (0.59) | NCF1ALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL440491 | 0.81 | NR4A2 (0.74) | NCF1LMNAALDH1A1CASP1CASP7 | |
| SCHEMBL28086396 | 0.81 | LMNA (0.44) | NCF1LMNAALDH1A1CASP1CASP7 | |
| SCHEMBL28220049 | 0.80 | NCF1 (0.54) | NCF1ALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL3531515 | 0.79 | LMNA (0.66) | LMNAALDH1A1MEN1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024101337-A1 | QUINAZOLINE DERIVATIVES | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081845-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4011877-A2 | METHOD OF TREATING ELEVATED PLASMA CHOLESTEROL | Institut de Cardiologie de Montréal (CA) | 2022-06-15 | — | — | EP | disclosed |
| US-9049878-B2 | Sweet flavor modifier | SENOMYX, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20120065166-A1 | Bone Modulators And Methods Therewith | ESPINA VIRGINIA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1150977-B1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| US-6699879-B1 | OBESITY, DIABETES, SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-02 | — | — | US | disclosed |
| EP-1150977-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047577-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | NCF1 4155/4885LMNA 3744/4885ALDH1A1 1363/4885 |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | NCF1 1011/4885LMNA 3046/4885ALDH1A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.